Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

EQL Pharma: Mellozzan® (melatonin) launched in the UK

EQL Pharma

EQL's key product Mellozzan® (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan® successfully in Germany, among other countries. Unlike many other countries in Europe, there is already a growing use of melatonin to treat children with ADHD and sleep problems in the UK. The melatonin tablet market had a turnover of around £10.8 million in 2024, with a volume growth of 32% compared to 2023.

Mellozzan® in the UK is expected to be expanded with the oral solution in 2026. The application is currently under review by the UK Medicines Agency.

About Mellozzan®

Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.

About Medice

Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with its own GxP capabilities in the development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of the "Medice - The Health Family" which aims to improve patient care by offering high-quality innovative pharmaceuticals, non-pharmacological interventions and value-added services. For more information, please visit www.medice.com.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.